Nitric oxide nightglow and Martian mesospheric circulation from MAVEN/IUVS observations and LMD-MGCM predictions

International audienceWe report results from a study of nitric oxide nightglow over the northern hemisphere of Mars during winter, the southern hemisphere during fall equinox and equatorial latitudes during summer in the northern hemisphere based on observations of the δ and γ bands between 190 and 270 nm by the Imaging UltraViolet Spectrograph (IUVS) on the MAVEN spacecraft. The emission reveals recombination of N and O atoms dissociated on the dayside of Mars and transported to the nightside. We characterize the brightness (from 0.2 to 30 kR) and altitude (from 40 to 115 km) of the NO nightglow layer, as well as its topside scale height (mean of 11 km). We show the possible impact of atmospheric waves forcing longitudinal variability, associated with an increased brightness by a factor 3 in the 140 - 200∘ longitude region in the northern hemisphere winter and in the -102∘ to -48∘ longitude region at summer. Such impact to the NO nightglow at Mars was not seen before. Quantitative comparison with calculations of the LMD-MGCM (Laboratoire de Météorologie Dynamique - Global Circulation Model) suggests that the model globally reproduces the trends of the NO nightglow emission and its seasonal variation, but also indicates large discrepancies (up to a factor 50 fainter in the model) in northern winter at low to mid-latitudes. This suggests that the predicted transport is too efficient towards the night winter pole in the thermosphere by ∼20∘ latitude north

Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes

OBJECTIVE - Proinsulin is a precursor of mature insulin and C-peptide. Higher circulating proinsulin levels are associated with impaired b-cell function, raised glucose levels, insulin resistance, and type 2 diabetes (T2D). Studies of the insulin processing pathway could provide new insights about T2D pathophysiology. RESEARCH DESIGN AND METHODS - We have conducted a meta-analysis of genome-wide association tests of ;2.5 million genotyped or imputed single nucleotide polymorphisms (SNPs) and fasting proinsulin levels in 10,701 nondiabetic adults of European ancestry, with follow-up of 23 loci in up to 16,378 individuals, using additive genetic models adjusted for age, sex, fasting insulin, and study-specific covariates. RESULTS - Nine SNPs at eight loci were associated with proinsulin levels (P < 5 × 10-8). Two loci (LARP6 and SGSM2) have not been previously related to metabolic traits, one (MADD) has been associated with fasting glucose, one (PCSK1) has been implicated in obesity, and four (TCF7L2, SLC30A8, VPS13C/ C2CD4A/B, and ARAP1, formerly CENTD2) increase T2D risk. The proinsulin-raising allele of ARAP1 was associated with a lower fasting glucose (P = 1.7 3 10-4), improved b-cell function (P = 1.1 × 10-5), and lower risk of T2D (odds ratio 0.88; P = 7.8 × 10-6). Notably, PCSK1 encodes the protein prohormone convertase 1/3, the first enzyme in the insulin processing pathway. A genotype score composed of the nine proinsulin-raising alleles was not associated with coronary disease in two large case-control datasets. CONCLUSIONS - We have identified nine genetic variants associated with fasting proinsulin. Our findings illuminate the biology underlying glucose homeostasis and T2D development in humans and argue against a direct role of proinsulin in coronary artery disease pathogenesis